Accession Number:



Phase I Trial of Intratumoral Administration of NIS-Expressing Strain of Measles Virus in Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

Mayo Clinic

Personal Author(s):

Report Date:


Pagination or Media Count:



Study approved by Mayo IRB on April 18, 2016, and by USAMRMCORPHRPO on May 6, 2016. All study staff completed IRB training. Dose volume charts have been developed to facilitate pharmacy orders. Study opened for enrollment on May 17, 2016. Study coordinators identified and assigned to the study by Mayo Clinic Cancer Center. Five patients have been enrolled in the study. They completed treatment per protocol and continue the follow up. None of the treated patients experienced side effects. With the first 3 patients we have completed the first dose level, and two patients have been treated by dose 2 level. Accrual of the third patient into dose 2 is ongoing. So far out of 5 treated patients two died to cancer progression. Others are undergoing follow up. A few additional patients are under evaluation for eligibility at this time.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]